An antiviral cyclic peptide.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Alisporivir is a cyclic peptide investigated for its antiviral properties (ChEBI).

Alisporivir on DrugBank
Alisporivir on PubChem
Alisporivir on Wikipedia




Structure image - Alisporivir


Supporting references

Link Tested on Impact factor Notes Publication date
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Small molecule In vitro Screening
Huh7.5 cells; Calu-3 cells; primary normal human bronchial epithelial cells; iPSC-derived AT2 cells; SARS-CoV-2 strain USA WA1/2020 8.11

Inhibited SARS-CoV-2 replication in Huh7.5 cells, Calu-3 cells, or primary normal human bronchial epithelial cells.


AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04608214 Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) Not yet recruiting Phase 2 Nov/01/2020 Aug/04/2021
  • Alternative id - APHP200552|2020-002295-13
  • Interventions - Drug: Alisporivir|Other: Standard of care (SOC)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Change in SARS-CoV-2 viral load in nasopharyngeal swabs|Viral Load Response Rate (VLRR)|Percentage of patients reporting each severity rating on an 8-point ordinal scale.|Change in National Early Warning Score scale|Changes in thoracic CT scan|Percentage of patients admitted to Intensive Care Unit (ICU)|Time to admission to Intensive Care Unit (ICU)|Percentage of patients requiring mechanical ventilation|Percentages of patients negative for SARS CoV 2 RNA in nasopharyngeal swabs|Time to negative viral load|Time to resolution of symptoms|Duration of need for supplemental oxygen|Duration of hospitalisation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or ECMO use|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Patient all-cause mortality|Cumulative incidence of any AE|Cumulative incidence of Grade 3 and 4 AEs|Cumulative incidence of SAEs